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Inflammatory bowel disease (IBD) including both ulcerative colitis andCrohn’s disease is increasingworldwide. Although diagnosis
is equally found in men and women, the chronicity of IBD poses a unique impact on the milestones of a woman’s life. As the
gastroenterologist becomes increasingly important in the health maintenance of patients with IBD, this review stresses the unique
gender issues in women with IBD related to menstruation, cervical cancer, sexual health, contraception, and menopause that may
affect the course of disease, treatment decisions, and quality of life.
1. Introduction
Inflammatory bowel disease (IBD) is a chronic idiopathic
inflammatory bowel disease which includes both ulcerative
colitis (UC) and Crohn’s disease (CD) [1, 2].The two diseases
are both inflammatory conditions but present very differently
and involve different parts of the gastrointestinal tract. UC
was first described by Wilks in the 1800s [3]. It is an
inflammatory disease that is characterized by continuous
inflammation of the colonic mucosa that extends proximally
from the rectum [1]. The natural history of the disease
ranges from periods of quiescent remission to flares. The
mainstay of treatment is pharmacologic therapy. However, up
to 30% of individuals will necessitate total proctocolectomy
due to refractory disease, dysplasia, or the development of
cancer [4, 5]. The standard surgical options include total
proctocolectomy and end-ileostomy, proctocolectomy with
ileoanal pouch anastomosis (IPAA), and, less frequently
recommended, abdominal colectomy with ileorectal anasto-
mosis [4]. Crohn’s disease was first reported by Crohn et al.
in 1932 [6]. It can involve any portion of the gastrointestinal
tract from mouth to anus. It is classically characterized by
skip lesions in which there are discrete areas of diseased
bowel separated by normal bowel and typically it spares the
rectum [2]. Approximately 50% of patients have their disease
involving the terminal ileum and colon, 30% have isolated
small bowel disease, 20% have isolated colonic disease, and
up to 25% will also have perianal complications [2]. Crohn’s
disease can present in many different ways often based on
the underlying disease phenotype. The three classic types of
Crohn’s disease include inflammatory disease (nonpenetrat-
ing and nonstricturing), stricturing disease, and fistulizing
disease. Similar to UC, the natural history of disease varies
between remission and flares. The mainstay of therapy is
pharmacologic management of disease [2]. However, surgery
will be necessary in up to 80% of individuals with 50%
undergoing a surgery within 10 years from their diagnosis
[5, 7]. UnlikeUC, the surgicalmanagement of Crohn’s disease
is not curative. Therefore, the types of surgery are dictated by
the presenting problem (e.g., stricture or fistula) and a goal of
removing the smallest amount of bowel necessary.
Both CD and UC are increasing in prevalence globally
with as many as 1.4 million individuals in the United States
and 2.2 million individuals throughout Europe [8, 9]. The
overall incidence of IBD in pediatrics is rising worldwide.
Benchimol et al. reviewed 139 studies from 32 different coun-
tries from 1950 to 2009 to assess the worldwide epidemiology
of childhood-onset IBD.They noted that, in studies reporting
statistical trends, there has been a 60% increase in childhood
onset Crohn’s disease and 20% increase in UC [10]. Similarly,
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the incidence of IBD in adults is also rising globally with
the highest prevalence in Europe and North America [11].
The peak incidence of IBD is between 15 and 30 years old
[12]. IBD affects men and women equally. An important
difference between pediatric onset and adult onset IBD is
that pediatric onset IBD is associated with more extensive
intestinal involvement and a more rapid progression of their
disease [13, 14].
However, because IBD is a chronic illness, the impact
of IBD on women is unique. IBD may affect the major
milestones of a woman’s life including menstruation, sex-
uality, family planning, and menopause. Rarely discussed
topics such as how medications and surgery may adversely
affect self-image are critical to broach with patient. As
the gastroenterologist becomes increasingly important in
the health maintenance of patients with IBD, this review
seeks to stress the unique gender issues in women with
IBD related to menstruation, cervical cancer, sexual health,
contraception, and menopause that may affect the course of
disease, treatment decisions, and the quality of life.
2. Body
2.1. Quality of Life. The overall reported quality of life (QOL)
with IBD is variable and is often dependent on symptom
severity [15, 16]. Often, CD is reported to have a greater
negative impact onQOL compared toUC [16]. One challenge
affecting the overall QOL is that typically individuals are not
comfortable discussing their gastrointestinal symptoms in an
open forum with friends and colleagues [16]. In a survey of
5,576 patients, 75% of patients reported that their symptoms
affected their ability to enjoy leisurely activities and 69%
reported that their symptoms affected their ability to perform
at work [15]. Importantly, though, over 70% of individuals
who were on therapeutic agents reported improvements
in their overall QOL [15]. Similarly, while the QOL with
severe uncontrolled UC or immediately postsurgery was
suboptimal, improvement inQOLwas already noted 1month
after ileostomy take-down and returned to normal within one
year after surgery for UC [17]. Potential predictors of reduced
QOL include those with a higher perceived level of stress, less
social support, greater number of disease relapses, and female
sex [18].
When therapeutic modalities are successful in putting
the disease in remission QOL is usually similar to the
general population. However, when symptoms are not well
controlled, especially in pediatrics, there can be a signifi-
cant reduction in QOL [19]. Additionally, when therapeutic
options result in side effects this further diminishes one’s
perception of QOL [20]. Importantly, the reduction in overall
QOL in adolescence with IBD may be present regardless
of disease activity. A study by MacKner et al. reported that
patients with IBD had poorer school functioning compared
to age matched controls [21].
Throughout this review the effects of women’s issues in
IBD and how they affect QOL will be addressed.
2.2. Menstruation
2.2.1. Puberty and Menarche. IBD may delay the onset of
menses in adolescence, especially when the disease is poorly
controlled [22, 23].The exact etiology for this delay is unclear.
Possible causes for this delay include growth failure from
being underweight and nutritional deficits [22]. Medication
usage, as the case with corticosteroids, also contributes to
growth retardation and delayed puberty [24]. Additionally,
in animal models, inflammatory mediators in active colitis
may also contribute to malnourishment and pubertal delay.
However, once disease is in a sustained remission, puberty
and menarche occur soon after [25].
2.2.2. Symptoms and Changes during Menstrual Cycle. The
hormonal changes during the menstrual cycle may affect
a multitude of chronic disease symptoms and IBD is no
exception [26]. In a study of 238 patients with IBD (151 CD,
87 UC) and 156 healthy controls, patients with CD were
more likely to complain of an increase in diarrhea prior to
and during menses, whereas patients with UC complained
of an increase in diarrhea only during menses [27]. A recent
study by Saha et al. found that changes in menses occurred
even prior to the diagnosis of IBD [28]. In the year prior
to the diagnosis of IBD, 21% of patients developed a change
in the duration of menstrual flow [28]. Additionally, those
suffering from dysmenorrhea had an increase in intensity of
menstrual pain. This resulted in a significantly lower quality
of life compared to those with more regular menstrual cycles.
Over time, though, cycles became more regular [28].
If the physician and/or patients are not aware of these
expected changes, many of them may be misinterpreted as
exacerbations of the underlying IBD [29]. Therefore, coun-
seling patients about expected fluctuations in symptoms that
occur during the menstrual cycle is important in improving
their overall quality of life.
2.3. Cervical Cancer Prevention and Screening
2.3.1. Risk of Cervical Cancer. Kane et al. reported that the
overall incidence of any abnormal pap smear in a woman
with IBD was 42.5% compared to 7% of controls [30]. Fur-
thermore, women with IBD were more likely to be diagnosed
with higher-grade lesions than controls [30]. Though not
statistically significant, there was a trend toward those on
immunosuppressants for greater than 6months to have more
abnormal pap smears [30]. The data on whether or not
thiopurines increase the risk of cervical dysplasia is equivocal
[31–33]. Recently, however, another population based study
raises the possibility that IBD alone, regardless of thiopurine
usage, may increase the risk of cervical neoplasia [34].
2.3.2. Screening for Cervical Cancer. Currently, the cervical
cancer screening is recommended in the general female pop-
ulation every 2-3 years [35]. However, immunosuppressed
patients, such as those with HIV, have recommendations to
undergo yearly pap smears [36]. Given the equivocal evidence
regarding the risk of cervical dysplasia from thiopurine usage,
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some practices, like ours, recommend yearly pap smears.
Nevertheless, yearly pap smears have not been advocated by
major societies. Despite this concern for cervical dysplasia
in this population, Singh et al. found that just over 50%
of women with IBD underwent pap smears at guideline
recommended intervals. Independent predictors of lower
adherence to pap smears were CD and immunosuppressant
usage [37].
2.3.3. Prevention of Cervical Cancer. Human papilloma virus
(HPV) vaccinations, such as Cervarix and Gardasil, target
HPV types 16 and 18, which are responsible for 70% of
cervical cancers. Currently the Advisory Committee on
Immunizations Practices (ACIP) recommends vaccinations
for girls 9 years to 26 years of age [38]. Given the risk of
abnormal pap smears, women on chronic immunosuppres-
sion are also candidates for HPV vaccination regardless of
sexual activity status. Despite the beneficial effects of HPV
vaccination, Wasan et al. found that the overall knowledge
of gastroenterologists regarding appropriate vaccinations is
poor [39].
2.4. Sexual Health
2.4.1. General Issues in Sexual Health. IBD can have a signi-
ficant impact on a woman’s sexual well-being [40]. Sexual
activity may be a major component in considering what
is “healthy.” Sexuality, defined as the desire for sex and
satisfaction with sexual activity, has been found to be lower
in IBD patients [41]. There are multiple causes for this
finding including the disease itself, medications, surgery,
and its influence on energy level, libido, mood, and body
image. Indirectly, there may be symptoms of fatigue and
poor body image following surgery and use of medications
like corticosteroids. Mar´ın and colleagues found that 50% of
women and 33% of men reported worsening sexual function
after the diagnosis of IBD [42]. The disease itself may lead to
issues with symptoms of diarrhea, fear of fecal incontinence,
flatulence, and fistula drainage [43]. Impaired sexual activity
is particularly worse in women with IBD compared to
men with IBD; women with IBD were more likely to have
impaired body image and decreased libido and engage in
less intercourse [44]. In another study, women with IBD had
lower sexual activity compared to age matched controls, but,
interestingly, partner satisfaction was equally high [41]. The
major factor affecting sexual activity, however, was related
to concomitant depressed mood rather than disease activity
[45]. As a result, in patients with reduced sexual satisfaction,
it is important to both assess disease related issues and also
screen for other potential causes like depression.
2.4.2. Sexual Issues after Surgery. Additional issues affecting
sexual well-being are surgical treatments for IBD. Following
surgical treatment for IBD, there is a significant concern
of sexual dysfunction and dyspareunia [46]. Following a
proctocolectomy in patients under 40, 33% of women com-
plained of reduced quality of sexual life and 22% noted
reduced satisfaction following intercourse after the surgery
[47]. However, other studies have observed an improvement
in sexual function. Metcalf et al. found that patients who
undergo proctocolectomy with formation of either a Kock
pouch or ileoanal anastomosis were more likely to increase
their frequency of intercourse and had a reduction in the
incidence of dyspareunia [48]. Damgaard et al. similarly
reported finding increased sexual function and quality of life
following ileal J-pouch anastomosis [49]. In a prospective
study following ileal pouch-anal anastomosis, Davies et al.
found that while abnormal sexual function decreased from
73% to 25% after surgery, the improvement in female sexual
function took an average of 12 months postoperatively [50].
The type of surgical approach, whether laparoscopy versus
conventional restorative proctocolectomy, did not lead to a
difference in quality of life outcomes; however, laparoscopy
is associated with improved cosmoses and body image which
can affect one’s sexual health [51]. In our center, our colorectal
surgeons favor a laparoscopic approach whenever feasible.
Stoma formation carries many concerns with regard to its
effect on sexual health. After formation of stoma, individuals
have concerns about appliance leakage, odor, and body image
[46]. Follick et al. surveyed patients with ostomies with 78%
reporting a decrease in sexual activity; 34% had decreased
enjoyment from sexual relations, and 41% felt sexual relations
were a problem [52]. However, following ileostomy, patients
noted unchanged or improved sexual function [53]. With
adequate patient counseling regarding possible issues that can
interfere with sexual relations and having adequate support
services for the patient to address these issues if/when they
come up, many of the concerns related to changes in sexual
relations after surgery can be mitigated [54, 55]. As a result,
we strongly recommend being proactive and initiating this
discussion about sexual well-being with patients as a routine
piece of the clinical assessment of women with IBD.
2.5. Fertility, Family Planning, and Contraception
2.5.1. Fertility. Womenwith IBD are often reluctant to discuss
issues of family planning with their gastroenterologists. Fear
of the unknown including likelihood of pregnancy, disease
activity, its effects on an unborn child, and heritability of
IBD in offspring may interplay with one another. This is
particularly evident in a 2009 survey of patients with IBD
who were queried on their views of subjective and objective
views about fertility. While 42% of patients described some
fear of infertility, the rate of those seeking medical infertility
advice was no different compared to the healthy population.
Specific concerns identified in this population included IBD
heritability, medication teratogenicity, and risk of congenital
abnormalities [56]. In light of these concerns,multiple studies
have unsurprisingly shown that voluntary childlessness is
more common in women with IBD compared to healthy
controls. In a study by Marri et al., 18% of CD and 14% of
UC patients chose voluntary childlessness compared to 6%
in healthy controls. Contraception use in the IBD cohort
was lower than controls prior to the diagnosis of IBD but
higher than healthy controls afterwards [57]. Similarly, a
recent survey found that nearly 80% of the women with IBD
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who did not have children in the study had chosen not to have
kids and did not have any fertility issues [58].
It is important to note though that fertility is in fact
reduced in cases where patients undergo surgery and have an
IPAA. A meta-analysis by Waljee et al. reported the risk of
infertility was increased threefold [59]. The weighted average
infertility ratewas 48%after IPAA [59].The exact cause of this
reduction in fertility is unknown. It is speculated that either
it is related to the surgical manipulation in the pelvic area
or secondary to adhesions resulting in damage to the repro-
ductive organs [60]. Therefore, while not an ideal surgery,
some may consider either a temporary diverting ileostomy
or temporary ileorectal anastomosis until after childbearing
is completed to avoid this risk reduction. However, Pabby et
al. found that women who had underwent IPAA were able
to achieve live births following in vitro fertilization at rates
comparable to women with UC without IPAA and women
unaffected by IBD [61].
2.5.2. Family Planning. It is thus important for the clinician to
broach the possibility of pregnancy and importance of family
planning. Ideally, women should have quiescent diseasewhen
conception occurs, as this portends a favorable prognosis
for both mother and baby. The presence of active disease
may cause lower rates of fertility, but, as mentioned above,
when disease is in remission, fertility is similar to those
without IBD [62, 63]. The risk of passing IBD on to an
offspring ranges from 1.6 to 5.2% with one parent having
the disease and up to 36% when two parents have the
disease [64, 65]. Only two of the medications, methotrexate
and thalidomide, used to treat IBD are category X agents
and should absolutely not be used [63]. The majority of
medications used to treat IBD are otherwise either category
B or category C [63]. If the disease is in remission, the effect
of IBD on pregnancy is generally thought to be minimal.
Some studies have indicated risks of preterm birth, low birth
weight, and small gestational age. However, all of these are
more significant when the disease is active [60, 63]. Given
the importance of staying on medication to treat the IBD
and risk of complications if the disease is/becomes active,
we recommend that all women with IBD who plan on
conceiving be seen by a high-risk obstetrician and followed
up closely by their gastroenterologist. A discussion regarding
themanagement during pregnancy is beyond the scope of this
review [63].
2.5.3. Contraception. Specific considerations should be given
when advising contraception use in women with IBD. While
all forms of contraception are available to this popula-
tion including barrier protection, oral contraception, and
intrauterine devices, the optimal method of contraception
should have a low failure rate and minimally interfere with
IBD. Failure rates of barrier protection as well as case
reports of IBD flares occurring after IUD insertion should be
considered [66, 67]. Authors have also suggested that the risk
of thrombosis in oral contraceptives (OCP)may theoretically
exacerbate a known risk of thrombosis in IBD [68]. However,
there have been no trials to date linking the use of OCPs and
compounded thrombosis risk in IBD. In our center, we do
not limit the use of OCP even in patients with inflammation.
We recommend usage of whatever contraception is recom-
mended as the ideal modality by the gynecologist.
The interaction between oral contraception and concomi-
tant medical therapy for IBD should also be considered.
Antibiotics are commonly used in IBD. It has long been
advised by physicians that use of antibiotics in the setting
of OCP decreases the efficacy of OCPs [69]. The American
College of Gynecology importantly notes though that this
has been based on anecdotal reports. According to their
2006 report, only rifampin has been shown to be associated
with lower oral contraceptive steroid levels [70]. The only
guidance for OCP use has been through small prospective
trials, which note that OCP levels were seen to be stable
[71–73]. Absorption of OCPs has not been shown to differ
fromhealthy controls based on predominantly ileal or colonic
disease [68], although some expert opinions still suggest
that there may be potential for decreased efficacy in CD
with small bowel resection and/or malabsorption [74–76].
If breakthrough bleeding occurs on long term antibiotic
therapy, alternative contraceptive methods should be used.
There has been some concern that OCP use can increase
the risk of developing IBD or cause an increase in flares. A
meta-analysis in 2008 found that, after adjusting for smoking,
exposure to OCPs increased the risk of IBD, in particular CD
[77]. In a prospective cohort study examining the incidence of
the development of IBD in the Nurse’s Health Initiative, OCP
use was associated with a small increase in the development
of CD but not UC [78].
Because of evidence linking OCP use and risk of IBD,
it has been postulated that OCPs may induce flares. In a
literature review of the interaction between OCPs and IBD,
Zapata et al. [68] found that the prevalence of relapse was
not statistically significant in CD [79] or UC [80]. In a large
prospective cohort of 331 women with CD, OCP use with
progesterone only, low dose estrogen (30–35mcg estrogen),
and high dose estrogen (50mcg estrogen) did not affect
relapse rates [81]. More recently, in a 2014 article, Gawron
et al. found that nearly 20% of women with IBD on OCPs
reported improved GI symptoms related to menses while on
OCPs [82]. As noted previously, there are case reports of IBD
flares within IUD days to 24 months after placement, but
larger studies and definite causality are lacking [66, 67].
2.6. Menopause
2.6.1. Menopause. Scant literature pertains to the effect
of IBD on menopause and vice versa. However, women
diagnosed with IBD may be diagnosed after the onset of
menopause and the influence of hormonal changes on disease
behavior is not clear.
A handful of articles give some insight into IBD and the
timing of menopause. A study by Lichtarowicz et al. surveyed
196 women with CD from Wales about menstruation cycles,
age of onset of menopause, smoking, and use of oral contra-
ceptives. Forty-eight of these women underwent physiologic
menopause with the mean age of menopause onset between
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46 and 47 in the IBD group compared to 49.6 years in healthy
controls [83]. In contrast, Kane and Reddy did not find any
difference in median age of menopause in patients with IBD
compared to healthy controls [84]. Additionally, there was no
difference in occurrence of flares prior to or following the
onset of menopause [84].
2.6.2. Hormone Replacement Therapy. Use of hormone rep-
lacement therapy (HRT) has been questioned since the
Women’s Health Initiative demonstrated an increase in risk
of breast cancer, coronary artery disease, stroke, and venous
thromboembolism [85]. HRT and its effect on IBD are
unclear. Interestingly, Kane’s study found a protective and
dose dependent effect of HRT on disease activity in the
postmenopausal state, with women with IBD on HRT 80%
less likely to suffer from flares compared to those who were
not on HRT [84].
More recently, use of HRT has been correlated with
increased risk of development of UC. Khalili et al. prospec-
tively followed up 108,844 women on HRT. The risk of
development of UCwas increased and further increased with
duration of HRT use [86]. This correlation was not seen with
development of CD. However, the correlation between HRT
and flaring IBD remains unknown.
3. Conclusion
Thehealthmaintenance of patient with IBDhas been increas-
ingly emphasized. IBD affects women in many important
ways. For the female patient diagnosed with IBD, gastroen-
terologists should be proactive with discussions about the
course of the disease and its impact on menstruation, family
planning, and menopause. In adolescence, careful proactive
counseling regarding impact of IBD on QOL is critical.
Physicians need to discuss with patients the effects both
IBD and the medications used to treat IBD have on the
onset of puberty and possible delays in onset of menarche.
Additionally, women should be counseled about the potential
increased risk in cervical cancer and means to reduce these
risks withHPV vaccination and pap smears.The effect of IBD
as well as the surgical treatments and the resultant impact
on sexual relations is significant. While some of the issues
may improve (e.g., ileostomy take-down), other issues like
depression need to be sought out by the physician. Physicians
should establish an open dialogue with patients early on
regarding their sexual health and any issues related to it.
While establishing this dialogue, careful attention to family
planning is critical. Patients should be counseled about the
use of OCPs and physicians should discuss how to optimize
their disease status prior to attempting any pregnancy. Aside
from patients with an IPAA, overall fertility should not be
affected by IBD. Given potential complications associated
with pregnancy we strongly encourage comanagement of
these patients with a high-risk obstetrician. Overall, coun-
seling the women with IBD about potential changes in
puberty, menstruation, fertility, pregnancy, sexual health,
and menopause is critical to optimizing their care. Such
discussions allow the patient to develop realistic expectations
and allay fears and concerns about the disease and its impact
on important milestones that often go unaddressed. Given
the knowledge deficit in the patient population, it is of
utmost importance to not only present these topics, but guide
women through any concerns and questions. Ultimately,
future studies are still needed to improve the overall medical
management and surgical management and to also clarify
ways to improve the QOL in women with IBD.
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